Macrolides and mortality in critically Ill patients with community-acquired pneumonia: A systematic review and meta-analysis

Critical Care Medicine

Volumn 42, Issue 2, 2014, Pages 420-432

  Sligl, Wendy I ^a   Asadi, Leyla ^a   Eurich, Dean T ^a   Tjosvold, Lisa ^a   Marrie, Thomas J ^b   Majumdar, Sumit R ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Community Acquired Pneumonia; Critical Care; Intensive Care; Macrolide; Mortality; Systematic Review

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE;

COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; HUMAN; META ANALYSIS; MORTALITY; PNEUMONIA, BACTERIAL;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; HUMANS; MACROLIDES; PNEUMONIA, BACTERIAL;

EID: 84893313755     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182a66b9b     Document Type: Article

References (54)

1. File TM Jr, Marrie TJ: Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010; 122:130-141
2. Heron M, Hoyert DL, Murphy SL, et al: Deaths: Final data for 2006. Natl Vital Stat Rep 2009; 57:1-134
3. Niederman MS, McCombs JS, Unger AN, et al: The cost of treating community-acquired pneumonia. Clin Ther 1998; 20:820-837
4. Almirall J, Bolíbar I, Vidal J, et al: Epidemiology of community-acquired pneumonia in adults: A population-based study. Eur Respir J 2000; 15:757-763
5. Sligl WI, Marrie TJ: Severe community-acquired pneumonia. Crit Care Clin 2013; 29:563-601
6. Parnham MJ: Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005; 18:125-131
7. Giamarellos-Bourboulis EJ: Immunomodulatory therapies for sepsis: Unexpected effects with macrolides. Int J Antimicrob Agents 2008; 32(Suppl 1):S39-S43
8. Simpson JL, Powell H, Boyle MJ, et al: Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155
9. Albert RK, Connett J, Bailey WC, et al; COPD Clinical Research Network: Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698
10. Schultz MJ: Macrolide activities beyond their antimicrobial effects: Macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 2004; 54:21-28
11. Baddour LM, Yu VL, Klugman KP, et al; International Pneumococcal Study Group: Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444
12. Martin-Loeches I, Lisboa T, Rodriguez A, et al: Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612-620
13. Restrepo MI, Mortensen EM, Waterer GW, et al: Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153-159
14. Rodríguez A, Mendia A, Sirvent JM, et al; CAPUCI Study Group: Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med 2007; 35:1493-1498
15. Giamarellos-Bourboulis EJ, Pechère JC, Routsi C, et al: Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia. Clin Infect Dis 2008; 46:1157-1164
16. Asadi L, Sligl WI, Eurich DT, et al: Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: A systematic review and meta-analysis. Clin Infect Dis 2012; 55:371-380
17. Ray WA, Murray KT, Hall K, et al: Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890
18. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012
19. Glanville JM, Lefebvre C, Miles JN, et al: How to identify randomized controlled trials in MEDLINE: Ten years on. J Med Libr Assoc 2006; 94:130-136
20. Default Search Strategies as per BMJ Clinical Evidence. Available at: Http://clinicalevidence.bmj.com/x/set/static/ebm/learn/665076.html. Assessed May 28, 2012.
21. Wells GA, Shea B, OConnell D, et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analysis. Available at: Http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed September 1, 2011
22. Egger M, Davey Smith G, Schneider M, et al: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634
23. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society: Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-S72
24. Eurich DT, Weir DL, Majumdar SR, et al: Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6:395-402
25. Aspa J, Rajas O, Rodriguez De Castro F, et al; Pneumococcal Pneumonia in Spain Study Group: Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010-1019
26. Bratzler DW, Ma A, Nsa W: Initial antibiotic selection and patient outcomes: Observations from the National Pneumonia Project. Clin Infect Dis 2008; 47(Suppl 3):S193-S201
27. Capelastegui A, España PP, Quintana JM, et al: [Evaluation of clinical practice in patients admitted with community-acquired pneumonia over a 4-year period]. Arch Bronconeumol 2006; 42:283-289
28. Charles PG, Whitby M, Fuller AJ, et al; Australian CAP Study Collaboration: The etiology of community-acquired pneumonia in Australia: Why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis 2008; 46:1513-1521
29. Cillóniz C, Ewig S, Ferrer M, et al: Community-acquired polymicrobial pneumonia in the intensive care unit: Aetiology and prognosis. Crit Care 2011; 15:R209
30. Dambrava PG, Torres A, Vallès X, et al: Adherence to guidelines empirical antibiotic recommendations and community-acquired pneumonia outcome. Eur Respir J 2008; 32:892-901
31. Grenier C, Pépin J, Nault V, et al: Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011; 66:1617-1624
32. Kontou P, Kuti JL, Nicolau DP: Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med 2009; 27:968-974
33. Le Bris-Tomczak A, Bedos JP, Billon C, et al: Antibiotic strategy in severe community-acquired pneumococcal pneumonia. Med Mal Infect 2012; 42:226-234
34. Marras TK, Jamieson L, Chan CK: Inpatient care of communityacquired pneumonia: The effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals. Can Respir J 2004; 11:131-137
35. Menéndez R, Torres A, Reyes S, et al: Initial management of pneumonia and sepsis: Factors associated with improved outcome. Eur Respir J 2012; 39:156-162
36. Pascual FE, Matthay MA, Bacchetti P, et al: Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000; 117:503-512
37. Rello J, Catalán M, Díaz E, et al: Associations between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28:1030-1035
38. Rosón B, Carratalà J, Fernández-Sabé N, et al: Causes and factors associated with early failure in hospitalized patients with communityacquired pneumonia. Arch Intern Med 2004; 164:502-508
39. Song JH, Oh WS, Kang CI, et al; Asian Network for Surveillance of Resistant Pathogens Study Group: Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: A prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008; 31:107-114
40. Wilson PA, Ferguson J: Severe community-acquired pneumonia: An Australian perspective. Intern Med J 2005; 35:699-705
41. Minhas R, Walter SAN, Rachlis A: Management of communityacquired pneumonia at a tertiary-care teaching hospital. Can J Hosp Pharm 2007; 60:245-256
42. Frei CR, Restrepo MI, Mortensen EM, et al: Comparison of health outcomes among severe community-acquired pneumonia patients treated empirically with a beta-lactam plus a macrolide versus a betalactam plus a fluoroquinolone. Value Health 2006; 9:A159
43. Shorr AF, Zilberberg MD, Kan J, et al: Azithromycin and survival in Streptococcus pneumoniae pneumonia: A retrospective study. BMJ Open 2013; 3:pii: E002898
44. Sligl WI, Hoang H, Eurich DT, et al: Macrolide use in the treatment of critically ill patients with pneumonia: Incidence, correlates, timing, and outcomes. Can J Infect Dis Med Microbiol (in press)
45. Wilson BZ, Anzueto A, Restrepo MI, et al: Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med 2012; 40:2310-2314
46. Mongardon N, Max A, Bouglé A, et al: Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: A multicenter study. Crit Care 2012; 16:R155
47. Karhu J, Ala-Kokko TI, Ohtonen P, et al: Severe communityacquired pneumonia treated with -lactam-respiratory quinolone vs. -lactam-macrolide combination. Acta Anaesthesiol Scand 2013; 57:587-593
48. Arnold FW, Wiemken TL, Peyrani P, et al; CAPO authors: Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2013; 107:1101-1111
49. Rodrigo C, Mckeever TM, Woodhead M, et al; British Thoracic Society: Single versus combination antibiotic therapy in adults hospitalised with community acquired pneumonia. Thorax 2013; 68:493-495
50. Arnold FW, LaJoie AS, Brock GN, et al; Community-Acquired Pneumonia Organization (CAPO) Investigators: Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. Arch Intern Med 2009; 169:1515-1524
51. Healy DP: Macrolide immunomodulation of chronic respiratory diseases. Curr Infect Dis Rep 2007; 9:7-13
52. ODwyer MJ, Mankan AK, Stordeur P, et al: The occurrence of severe sepsis and septic shock are related to distinct patterns of cytokine gene expression. Shock 2006; 26:544-550
53. Spyridaki A, Raftogiannis M, Antonopoulou A, et al: Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: Results from a randomized clinical study. Antimicrob Agents Chemother 2012; 56:3819-3825
54. Paul M, Nielsen AD, Gafter-Gvili A, et al: The need for macrolides in hospitalised community-acquired pneumonia: Propensity analysis. Eur Respir J 2007; 30:525-531